ROIVANT SCIENCES LTD. Cash and Restricted Cash
ROIVANT SCIENCES LTD. (ROIV) had Cash and Restricted Cash of $1.26 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.26B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.43B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.49B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.25B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $1.26B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.43B 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.49B 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $1.25B 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $1.25B 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $2.73B 10-K · filed 2026-05-20 | |
| 2024-12-31 | $2.00B 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $1.97B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $5.69B 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $6.51B 10-K · filed 2025-05-29 | $6.55B 10-K · filed 2024-05-30 |
| 2023-12-31 | $6.69B 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $1.42B 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.45B 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $1.69B 10-Q · filed 2024-08-09 | |
| 2022-12-31 | $1.54B 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $1.61B 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.96B 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $2.07B 10-K · filed 2024-05-30 | |
| 2021-12-31 | $2.23B 10-Q · filed 2023-02-13 | |
| 2021-09-30 | $2.51B 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $2.01B 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $2.14B 10-K · filed 2023-06-28 | |
| 2020-12-31 | $2.15B 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $2.39B 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.31B 10-Q · filed 2021-09-21 | |
| 2020-03-31 | $2.27B 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |